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 Chapter 1 
 Regulation of IFN-γ Expression 
 John  Fenimore and  Howard  A.  Young 
 Abstract  Interferon gamma, referred to here as IFN- γ , is a major component in 
immunological cell signaling and is a critical regulatory protein for overall immune 
system function. First discovered in 1965 (Wheelock Science 149: (3681)310–311, 
1965), IFN- γ is the only Type II interferon identifi ed. Its expression is both posi-
tively and negatively controlled by different factors. In this chapter, we will review 
the transcriptional and post-transcriptional control of IFN- γ expression. In the tran-
scriptional control part, the regular activators and suppressors are summarized, we 
will also focus on the epigenetic control, such as chromosome access, DNA meth-
ylation, and histone acetylation. The more we learn about the control of this regula-
tory protein will allow us to apply this knowledge in the future to effectively 
manipulate IFN- γ expression for the treatment of infections, cancer, infl ammation, 
and autoimmune diseases. 
 Keywords  IFN- γ •  Transcriptional control •  Epigenetic control •  LncRNA • 
 MicroRNA •  Activator •  Suppressor 
1.1  Introduction 
 Interferon gamma, referred to here as IFN- γ , is a major component in immunologi-
cal cell signaling and is a critical regulatory protein for overall immune system 
function. First discovered in 1965 [ 1 ], IFN-γ is the only Type II interferon identi-
fi ed. Functionally it is a homodimer with an antiparallel interlocking structure, lack-
ing beta sheets but possessing six alpha helixes per monomer. In humans the IFN-γ 
gene is found on chromosome 12q15 [ 2 ] and in mice on chromosome 10D2 [ 3 ]. The 
human gene for IFN-γ has four exon regions and three intron regions, covering 4.04 
kbps [ 4 ]. The receptor complex for IFN-γ, IFNGR1 and IFNGR2, is almost 
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ubiquitous in all mammalian cells, save erythrocytes. In addition, the structure of 
IFN-γ is much conserved in studied jawed vertebrates [ 5 ]. 
 IFN-γ’s effects on cells are notable, having been shown to modulate the expres-
sion of over 2,300 human genes [ 6 ]. While of the functions of different interferons 
are often redundant, a lack of normal IFN-γ expression is linked with cases of 
heightened weaknesses to some diseases even in the presence of other interferons. 
As discussed by Kaufmann and Booty et al. [ 7 ,  8 ], when expression of IFN-γ is low, 
susceptibility to mycobacterial and fungal infections is common; this shows the 
need for IFN-γ expression to fi ght disease and depicts the nonredundant functions 
of IFN-γ’s maintenance of host resistance [ 7 – 10 ]. 
 Unlike other interferons, even though IFN-γ does possess an antiviral capacity, it 
is more notable for its broader ability to stimulate and modulate the immune system. 
IFN-γ triggers the immune responses that lead to phagocytosis and increased 
expression of the MHC receptors on the surface of cells. This is further highlighted 
by IFN-γ being used to treat chronic granulomatous diseases, a group of inherited 
immune disorders in which white blood cells fail to control bacterial infections, thus 
causing severe infections in the skin, liver, lungs, and bone as pathogens are con-
tained in granules, but not consumed via phagocytosis [ 7 ]. In turn the presence of 
high amounts of IFN-γ has been linked to infl ammation. In some diseases such as 
multiple sclerosis, an autoimmune disease involving infl ammation in the brain and 
spinal column, IFN-γ was present in abnormally high levels in affected tissues [ 12 ]. 
IFN-γ has also been found to be involved in other chronic diseases such as Type 1 
diabetes, where IFN-γ overexpression has been linked to autoimmune dysfunction, 
as infi ltration by T cells expressing IFN-γ into islets containing pancreatic beta cells 
results in destruction of beta cells [ 13 ,  14 ]. 
 The activity of IFN-γ is noted as being involved in the activation, growth, and 
differentiation of T cells, B cells, macrophages, natural killer (NK) cells, and other 
cell types such as endothelial cells and fi broblasts, thus making it vital to the infl am-
matory response and to cell-mediated immune responses [ 4 ]. The innate and adap-
tive immune systems rely on controlled IFN-γ expression to preserve the balance 
between an effective host immune response and the development of autoimmune 
disease. For this reason, it is very important to understand the pathways that regulate 
the expression of IFN-γ. 
1.2  Transcriptional Controls 
 IFN-γ gene expression is controlled by a very complex system of regulation. IFN-γ 
has been noted to be normally expressed by cells from the immune system, such as 
the natural killer, or NK, cells and natural killer T, or NKT, cells which are both 
involved in the innate immune response. IFN-γ is also expressed during adaptive 
immune responses via CD4 + Type 1 helper (Th1) T cell, or CD4 + cells, and CD8 + 
cytotoxic T lymphocyte effector cells, or CD8 + cells. The expression of IFN-γ is one 
of the defi ning traits of CD4+ Th1 cell-type immune cells [ 11 ]. The differentiation 
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of immune cells into cells that produce IFN-γ or inhibition of such differentiation is 
also inherent to the amount of IFN-γ that is expressed by a host undergoing an 
immune response. Production of IFN-γ is controlled at several levels, including 
epigenetic changes, chromosomal access, cell surface signaling, transcription factor 
binding to promoters and enhancers, mRNA stability, and long noncoding RNA 
(LncRNA) interactions with the IFN-γ locus. Given the importance of IFN-γ to host 
immune function, it is not surprising that this single gene is regulated at many dif-
ferent levels. 
 Some regions of the genome are noted as being important for the control of 
IFN-γ expression in specifi c cell types but not in others. For instance, the region 
92–18 bp upstream of the start of transcription is noted as being vital for expression 
in human T cells and NKT cells, but not NK cells [ 15 ]. More work, illuminating the 
progress of our understanding of IFN-γ epigenetics, has demonstrated the impor-
tance of conformational changes to the structure of the IFN-γ locus and factors that 
affect access to the site [ 16 – 18 ]; this shows there are multiple mechanisms impact-
ing the transcription of this gene. 
1.2.1  Epigenetic Control 
 The role of access to and control of genetic information is an important factor when 
discussing the process of transcription. The IFN-γ gene is no exception, with several 
methods of epigenetic control affecting gene expression. However understanding 
the specifi c details of this control is a developing science. Specifi c areas of con-
served noncoding sequences, or CNS, are vital for the expression of IFN-γ as rele-
vant CNS regions are present before and after the transcription start site. Of great 
interest is the difference between their roles in different cell types. For example, it 
has been reported that CNS-30 can be deleted from NK cells without a loss of IFN-γ 
expression, while other cells that express IFN-γ require it for full transcription [ 15 ]. 
T cells require the presence of CNS-2, and all NKT and some T cells require the 
CNS present at +20 [ 17 ]. NK cell gene expression may also be enhanced by access 
to CNS-2 and CNS+20, but these regions are not required for basal IFN-γ gene 
expression [ 17 ]. Alternatively, CNS-16 has different effects depending upon the cell 
type; in NK cells it upregulates the expression of IFN-γ, but it is not required for 
transcription, while in the CD4 + Th2 cells, suppression of IFN-γ expression requires 
this region [ 17 ]. 
1.2.1.1  Chromosomal Access/DNA Methylation/Histone Acetylation 
 Chromatin condensation, by preventing or allowing access to the promoter or other 
regulatory elements of a gene, is a fi rst step in controlling gene expression. With 
respect to IFN-γ, expression is regulated fi rst via chromatin modifi cation. This is 
shown by the differences between nonactivated T cells and activated T cells with 
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regard to the chromatin density around the IFN-γ gene [ 17 ]. The compression of the 
IFN-γ region has a marked difference when comparing Th1, Th2, and naïve T cells, 
as observed from a chromatin conformational capture assay [ 16 ]. This is also appar-
ent in NK cells, which also have low chromatin density around the transcription 
start site indicating easier access to the promoter for binding of the required tran-
scription factors and RNA polymerase [ 17 ]. 
 Additional regulation of the expression of IFN-γ comes in the form of DNA 
methylation, which occurs when cytosine is converted to 5-methylcytosine at CpG 
nucleotides, and as a result prevents direct interactions with specifi c transcription 
factors to those regions of the DNA. The IFN-γ CNS-34, IFN-γ CNS-22, the IFN-γ 
promoter, and IFN-γ CNS+29 are methylated in naïve T helper cells, and methyla-
tion is lost as T helper cells progress through their differentiation pathways [ 19 ,  20 ]. 
The difference in methylation of DNA is notable in cells that do not express IFN-γ, 
where the locus is highly methylated, indicating that the methylation of specifi c 
transcription factor binding sites is an additional mechanism of transcriptional con-
trol. Contrasting this, hypomethylation, which is observed between the −200 and 
+1 positions of the IFN-γ promoter, contributes to the expression of the gene in 
activated Th1 and NK cells, through binding of transcription factors to those regula-
tory regions [ 20 ]. A target for methylation is a SnaBI restriction enzyme recognition 
site that is highly conserved in all species and is present at −52 bp in the  IFN - γ 
promoter [ 17 ,  18 ]. Demethylation of this SnaBI site is rapid during the processes of 
antigen activation, differentiation, and proliferation of T cells [ 17 ]. Of importance 
NK cells do not have notable methylation at this site, and in NK cells, cytokine 
stimulation of IFN-γ expression (e.g., IL-12) results in the rapid demethylation of 
the broader IFN-γ locus [ 17 ]. 
 Histone acetylation, another method of restricting transcription of a gene, is a 
reversible modifi cation of DNA that regulates chromatin access. Histone acetyla-
tion of the IFN-γ locus is of interest because when naïve T cells are initially stimu-
lated, the loci for the IFN-γ and IL-4 genes are unpacked by histones [ 17 ]. The 
process of histone acetylation changes after differentiation, with 50 kb of DNA both 
up- and downstream from the IFN-γ locus being closed off in non-IFN-γ expressing 
CD4 + Th2 cells [ 17 ]. This can also be observed by depriving the activated Th1 cells 
of STAT4, thus suggesting that active binding of STAT4 driven by IL-12 is critical 
for maintaining an open chromatin conformation at the IFN-γ locus [ 22 ]. 
Additionally, in T cells it has been shown that chromatin confi rmation is driven 
through an interplay of T-cell-specifi c T-box transcription factor (T-bet) and GATA3, 
which are transcription factors we will discuss later in this chapter. T-bet notably 
keeps the area where IFN-γ is located accessible via histone acetylation, while 
GATA3 seems to prevent the action of T-bet in keeping the IFN-γ locus accessible 
[ 17 ,  18 ]. This interaction between T-bet and GATA3 is notably absent in NK cells 
as the CNS regions that impact IFN-γ gene expression have, even in the absence of 
stimulation and active transcription, similar histone-acetylated domains as com-
pared to that found in activated T cells [ 18 ]. 
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1.2.1.2  Chromatin Positioning 
 Chromatin may form blocks to transcription or contrastingly cause specifi c areas of 
DNA to be more accessible; this is done not only via compression but also via mov-
ing elements away or toward enhancers. Chromatin may also cause movement in the 
three-dimensional space the gene occupies to prevent the association of transcrip-
tion factors or to facilitate such binding, via chromatin looping. This accessibility is 
observed via a notable change in the conformation of the IFN-γ locus [ 16 ]. CCCTC- 
binding factor, or CTCF, is a zinc fi nger transcription factor that binds the core 
CCCTC sequence [ 21 ]. These proteins have been described as suppressors for 
which there are three binding sites across the IFN-γ gene locus. These sites have 
been defi ned as markers that have been used to denote the limits of this locus [ 22 ] 
and have also been depicted to create a loop in active T cells which has been hypoth-
esized to be required for protection of the gene from heterochromatin silencing and 
to increase the effi ciency of expression [ 17 ]. 
1.2.1.3  LncRNAs 
 Long noncoding RNAs, or lncRNAs, are noted as being inhibitors of transcription 
via interactions between sections of RNA greater than 200 bp that are transcribed 
alongside other regions of chromatin that link to and inhibit the action of proteins 
and RNA. The role of these lncRNAs in the enhancement or suppression of tran-
scription is a developing fi eld of study as their activity is becoming more defi ned. 
For example, the ncRNA repressor of the nuclear factor of activated T cells, or 
NRON, is a negative regulator of the transcription factor (NFAT), which interacts 
with the IFN-γ promoter [ 23 ]. This inhibition of NFAT by NRON is caused by the 
formation of protein and RNA complexes, resulting in sequestration of NFAT in the 
cytosol, away from the DNA [ 23 ]. It has also been reported that Theiler’s murine 
encephalitis virus possible gene 1, or TMEVPG1, also named nettoie Theiler’s pas 
Salmonella, or NeST, is the fi rst identifi ed lncRNA to regulate expression of IFN-γ 
[ 24 ]. NeST is located 170 kb downstream from the IFN-γ gene and transcribed from 
the antisense strand relative to IFN-γ; the 33 kb NeST gene is spliced into a 1.7 kb 
RNA transcript in human cells [ 24 ]. Studies have shown that NeST’s expression in 
both mouse and human is Th1 T-cell selective and dependent on STAT4 and T-bet 
[ 24 ]. Due to this pattern of expression and its structural traits, it is believed that 
NeST associates with WD repeat-containing protein 5, or WDR5, to promote his-
tone H3 lysine 4, drive methylation to enhance chromatin accessibility, and con-
versely decrease attraction of local histones at the nearby IFN-γ locus, thus 
promoting transcription [ 17 ]. 
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1.2.1.4  miRNAs 
 MicroRNAs, or miRNAs, are between 18 and 25 nucleotides long and are noncod-
ing RNAs that suppress gene expression by binding to the 3′ UTR of target genes, 
resulting in either translation inhibition or mRNA degradation. A broader role for 
miRNA control of IFN-γ expression was demonstrated by studies demonstrating 
that the elimination of the Dicer gene, vital for the processing of microRNAs, 
increased the expression of IFN-γ in T cells [ 25 ]. Interestingly this effect has been 
noted in CD4 + TH2 cells indicating that there may be some changes to the epi-
genetics in the cells as a result of the inhibition of miRNA processing [ 25 ]. 
 Recently studies have shown that the miRNA, miR-223, which is notably 
enhanced by estrogen, positively regulates the expression of IFN-γ via inhibition of 
anti-infl ammatory elements such as IL-10 [ 26 ]. In other studies, microRNA-146a 
and microRNA-146b both suppress the activity of TRAF6 and IRAK1 protein 
expression, factors that are important for the function of the IFN-γ promoter, and 
thus cells expressing these miRNAs show decreased IFN-γ expression [ 27 ,  28 ]. 
Studies have also shown that miR-29 suppress IFN-γ production by directly target-
ing IFN-γ mRNA and enhancing its degradation [ 29 ]. However contrasting experi-
mental evidence reports that miRNA-29 inhibition is driven via degradation of the 
T-box transcription factor T-bet mRNA instead of the IFN-γ mRNA [ 30 ]. Additional 
studies focused on miR-155 have shown that in NK cells this miRNA increases the 
expression of IFN-γ when NK cells are stimulated, notably by both IL-18 and IL-12 
[ 31 ]. miR-155 is observed having its own expression increased when the NK cells 
are stimulated with IL-18 and IL-12 via downregulating SHIP1, a phosphatase, that 
in turn suppresses NF-kB activity, a transcription factor known to bind to the IFN-γ 
locus and stimulate transcription [ 31 ,  32 ]. 
1.3  Inducers of IFN-γ 
 IFN-γ is part of a system of biological signals that can induce substantial changes 
inside the cell and in the host overall. As such it must be regulated, since it is not 
passively expressed and different signals regulate expression either by enhancing or 
inhibiting gene expression. These signals come in many forms, but the primary 
methods are dependent upon cell activation through signaling via cell surface recep-
tors. Regulation of IFN-γ expression is largely driven by activators like transcription 
factors such as T-bet and NFAT and specifi c inhibitors, like TGF-beta, in CD4 + Type 
1 helper T cells. Methods to manipulate this upregulation involve specifi c systems 
using phosphorylation of transcription factors, driven by activation of multimeric 
receptors of cytokines linked to Janus kinases (JAK) activation, while inhibitory 
signals act through inhibition of these signaling cascades and their receptors result-
ing in inhibition of the specifi c transcription factors required for IFN-γ transcription 
[ 33 – 37 ]. 
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1.3.1  IL-2 
 IL-2 is a cytokine with three surface receptor subunits, alpha, beta, and a common 
gamma chain. The presences of these receptor subunits determine the level of affi n-
ity in each immune cell type for gene activation. For example, the beta and gamma 
chains together form a complex that binds IL-2 with intermediate affi nity on NK 
cells, while all three receptor chains form a complex that binds IL-2 with high affi n-
ity on activated T cells [ 33 ]. The stimulated signaling pathways upregulate IFN-γ 
expression but also notably upregulate the expression of SOCS1 which functions to 
prevent overexpression of IFN-γ [ 38 ]. Suppressor of cytokine signaling, or SOCS1, 
is a suppressor of IFN-γ expression that interacts with the tyrosine kinase (TYK), 
Jak1, and inhibits expression downstream by reducing STAT phosphorylation [ 33 ]. 
 IL-2 is also noted for triggering the binding of a STAT5 a/b heterodimer to a 
STAT5-binding element −3.6 kb from the transcription start site of the IFN-γ gene 
[ 39 ,  40 ] (Fig.  1.1 ).
1.3.2  IL-12/STAT4 
 Interleukin 12, or IL-12, is a cytokine heterodimer that can induce IFN-γ transcrip-
tion and cause nuclear accumulation of IFN-γ mRNA in CD4 + T helper cells and 
NK cells. At activation, two subunits of the IL-12 receptor which is a heterodimer 
comprised of the beta-1 and the beta-2 chains of the receptor come together to acti-
vate the receptor-associated Janus kinases, JAK2 and TYK2 [ 33 ,  40 ]. STAT4 is then 
phosphorylated by these tyrosine kinases and translocated into the nucleus to acti-
vate gene transcription. The pSTAT4 then interacts with IRF-1 and ERM to activate 
their binding to the IFN-γ promoter [ 14 ,  41 ,  42 ]. This activation also takes place in 
NK cells and is independent of most other forms of IFN-γ stimulation [ 23 ]. IL-12 
 Fig. 1.1  The archetypal motif of the receptor and cytokine structure to stimulate STATs. The 
interaction of a cytokine causes the dimerization of surface receptors which in turn cause 
phosphorylation- driven changes which cascade to affect transcription 
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has been noted to be dependent on STAT4 to induce expression of IFN-γ as STAT4 
is critical for maintaining an open chromatin conformation at the IFN-γ locus [ 17 , 
 43 ]. Furthermore transcriptional activity of T-bet, induced by IFN-γ, appears to 
increase the expression of IL-12 receptor beta 2 [ 43 ], thus demonstrating a feedback 
loop that enhances the cell response to IL-12. 
 IL-12 stimulation of cells results in an accumulation of IFN-γ mRNA in the 
nucleus, and release of this accumulated IFN-γ mRNA into the cytoplasm is drasti-
cally increased by the presence of interleukin 2, or IL-2 [ 44 ]. It has been hypothe-
sized that this increased release of mRNA may be a form of priming cells to release 
more IFN-γ mRNA when they encounter a second signal, creating a method of 
regulation that prevents overexpression but allows the cell to have a strong response 
when needed. It has been shown that both IL-2 and IL-12 in combination promote a 
steady release of IFN-γ over time, notably more than either signal alone, thus dem-
onstrating a synergistic response of the cell when multiple activating signals are 
encountered [ 44 ]. 
 These previously described pathways of IFN-γ expression when CD4 + cells are 
stimulated by IL-12 can occur only if the T-bet binding region is not blocked by the 
dual zinc fi nger transcription factor, GATA-binding protein 3 or GATA3 [ 45 ]. The 
GATA3 transcription factor does not affect the IFN-γ promoter region directly, but 
instead affects the downregulation of STAT4, thus preventing signaling needed to 
induce IFN-γ expression. GATA3 is in turn shown to be stimulated by exposure of 
a naïve T cell to interleukin 4 [ 45 ]. 
 STAT3 has been reported to have variable effects in NK cells and their expres-
sion of IFN-γ. It has been noted that STAT3 regulates IFN-γ production by binding 
the IFN-γ promoter upon stimulation of IL-12. However STAT3 has not been shown 
to be required for IFN-γ expression by NK cells [ 46 ,  47 ]. 
 It is important to note the synergistic effect of cytokines in regard to IFN-γ gene 
expression. A very strong synergy between IL-12 and IL-18 for IFN-γ expression is 
driven by the upregulation of receptors on cells that have been exposed to one or the 
other cytokines; the IL-12 beta-2 receptor chain has been noted to be upregulated by 
IL-18 and IL-12 can upregulate the IL-18 alpha receptor chain [ 48 ,  49 ], thus stimu-
lating the target cell to be maximally responsive to these cytokines. 
1.3.3  IL-15 
 Interleukin 15, or IL-15, is a heterodimeric cytokine that triggers IFN-γ gene expres-
sion through binding to a heterodimeric IL-15 receptor [ 35 ]. Signaling occurs 
through Janus kinases Jak 1 and Jak 3 activation which in turn phosphorylates 
STAT3 and STAT5. Studies have shown the responsiveness of CD8 + cells to IL-15 
results in the maintenance of CD8+ T-cell survival, thus affecting the host’s overall 
production of IFN-γ [ 35 ,  41 ]. 
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1.3.4  IL-18 
 A member of the IL-1 family, interleukin 18 (IL-18) (originally designated inter-
feron gamma-inducing factor), induces the transcription of IFN-γ. The surface 
receptors of IL-18 are well characterized; the receptors are heterodimeric with a 
region for the binding of the ligand, the IL-1 receptor-related protein (IL-1Rrp), and 
the signal transducing subunit or the accessory protein-like subunit (AcPL) [ 36 ]. 
Once activated, this causes a signal cascade involving MYD88, the IL-1 receptor- 
associated kinase (IRAK), TNF receptor-associated factor 6, and the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) [ 34 ]. NF-kB is shown to 
bind and enhance activity of the IFN-γ promoter, increasing expression of IFN-γ 
[ 50 ]. NF-kB additionally undergoes a chain of interactions to stimulate the activa-
tion of STAT4 which stimulates the production of IFN-γ [ 52 ,  53 ]. 
 Interleukin 10 (IL-10) is characterized as inhibiting the function of NF-kB and 
thus is considered an inhibitor of IFN-γ expression [ 54 ]. 
1.3.5  IL-27/STAT1/STAT3 
 Interleukin 27 (IL-27), a heterodimeric cytokine from the IL-12 family, enhances 
IFN-γ production by activated T cells and NK cells [ 33 ]. One such induction of 
expression is activated via IL-27’s interactions with a dimeric receptor comprised of 
the interleukin-27 receptor alpha chain (IL27Ra) and glycoprotein 130 (gp130) 
[ 55 ]. Upon binding of IL-27 to this receptor, two arms of Janus kinases are acti-
vated: Jak1 linked to the IL27Ra and Jak2, Tyk2, and Jak1 linked to gp130 [ 55 ]. 
Triggering the phosphorylation of STAT1 and STAT3, this causes the transport of 
the pSTAT1/3 heterodimer to the nucleus where it activates the T-bet promoter, 
resulting in increased T-bet and subsequent IFN-γ expression [ 55 ,  56 ]. 
1.4  Positive Transcriptional Control Factors 
 IFN-γ production is highly variable and cells do not express IFN-γ in a resting state. 
Thus there are numerous methods to activate immune cells to express this cytokine 
and vary its levels of expression. These controls are driven by transcription factors 
that form complexes on specifi c regions of DNA to control the level of transcription 
via RNA polymerase 2 [ 57 ]. In this section we will discuss the transcription factors 
involved in regulating IFN-γ expression and briefl y summarize our understanding 
of their activation and activity (Fig.  1.2 ).
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1.4.1  T-bet 
 T-bet, or the T-cell-specifi c T-box transcription factor, is considered one of the most 
important controls for the expression of IFN-γ. T-bet has been defi ned as a key fac-
tor in T-cell differentiation and is expressed in many cell types in the immune sys-
tem. However in many regards, it has been seen as the endpoint that other signal 
pathways must reach to stimulate the expression of IFN-γ or as the target that needs 
to be blocked to prevent expression [ 58 ]. Recent studies have shown T-bet is required 
for IFN-γ production and lineage commitment of CD4 + T cells, but not of CD8 + T 
cells [ 45 ]. Using T-bet KO mice, it was shown that, when stimulated, CD4+ T cells 
had a profound defi ciency in IFN-γ expression [ 59 ]. Contrastingly it was deter-
mined there is little difference in IFN-γ expression in stimulated CD8 + cells with or 
without T-bet [ 59 ]. Furthermore IL-12 has also been noted to induce T-bet in an 
IFN-γ receptor and STAT1-independent manner in CD8 + T cells [ 60 ]. Induction of 
T-bet results in upregulation of IL-12RB2, a receptor essential for responsiveness to 
IL-12, and differentiation to a CD4+ Th1 cell type [ 34 ]. However studies have 
shown that T-bet represses the Th2 lineage commitment through a tyrosine kinase- 
mediated interaction that interferes with the binding of GATA3 to its target DNA 
[ 61 ]. Making T-bet both a suppressor and an enhancer depending on the perspective 
of Th1/Th2 T-cell determination indicates that T-bet has a broader infl uence on 



























 Fig. 1.2  The IFN-γ gene, depicting general structure and relative locations of protein-binding 
sites 
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1.4.2  Eomes 
 In CD8+ T cells, the primary driver of IFN-γ expression is via the transcription fac-
tor Eomesodermin (Eomes), which functions independent of T-bet [ 62 ]. However it 
has been reported that there is synergistic effect when both Eomes and T-bet tran-
scription factors are expressed [ 63 ]. The activity of Eomes was also noted to increase 
phosphorylated STAT4 in CD8+ T cells, further promoting IFN-γ transcription [ 64 ]. 
Experiments with T-bet −/− CD8 + T cells have demonstrated normal IFN-γ expres-
sion, while Eomes −/− CD8+ cells did not express IFN-γ at notable levels, indicat-
ing a critical role for Eomes in CD8+ T-cell IFN-γ transcription [ 62 ,  63 ]. 
1.4.3  AP-1/CREB/ATF-2 
 Activating promoter 1, or AP-1, has been linked to the activity of the IFN-γ pro-
moter [ 64 ]. AP-1 has been reported to enhance the activity of NFAT proteins through 
the formation of complexes with these transcription factors [ 42 ]. 
 It has been shown that c-Jun, cAMP response element-binding protein (CREB), 
and ATF-2 are essential for activation-induced transcription of IFN-γ, and c-Jun 
binds preferentially to the IFN-γ proximal element at -52 as a heterodimer with 
ATF-2 [ 42 ]. The c-Fos and c-Jun transcription factors form a heterodimer known as 
activator protein 1 (AP-1), part of a subset of a large family of transcriptional con-
trol proteins, which in turn forms another complex with NFAT [ 65 ]. CREB or cAMP 
response element-binding protein is a known transcription factor closely associated 
with AP-1 that has been shown to bind to the proximal IFN-γ promoter −73 to −48 
bp upstream of the transcription start site [ 64 ]. This strongly implicates the involve-
ment of CREB proteins in the regulation of IFN-γ expression [ 65 ]. 
1.4.4  NFAT 
 Nuclear factor of activated T-cell (NFAT) binding sites have been identifi ed at posi-
tions −280 bp to −270 bp and −160 bp to −155 bp upstream from the IFN-γ tran-
scription start site, and studies show that they are required for full activity of the 
IFN-γ promoters in T cells [ 42 ,  66 ]. This effect is documented by experiments that 
demonstrated decreased levels of expression by full-length IFN-γ promoter-reported 
constructs with promoter regions that contain mutations in one or both of the NFAT- 
binding sites [ 66 ,  67 ]. 
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1.5  Negative Transcriptional Controls 
 Overexpression of a specifi c signal can lead to drastic problems in all biological 
systems. In the immune system, such overexpression of a specifi c gene can cause 
autoimmune responses that can have far-reaching consequences to a host. IFN-γ is 
a powerful immunoregulator and the ability to turn the signal off is in many ways 
just as important as its activation. While not as fully understood as activating sig-
nals, characterization of the inhibitory signals leading to decreased expression of 
IFN-γ is proving vital to our understanding of the regulation of this gene. 
1.5.1  Homeobox/Prox1 
 Prospero-related homeobox (Prox1) is a suppressor of the expression of IFN-γ in T 
cells; however, it does not typically function to suppress the genes as a homeobox 
gene would normally be expected to function. It has been reported that Prox1 does 
not bind to the promoter region of IFN-γ but that it uses a method of facilitating a 
conformational change with a protein intermediary to inhibit the synthesis of IFN-γ 
mRNA [ 68 ]. The nuclear receptor peroxisome proliferator-activated receptor 
gamma (PPARγ) has been shown to link to the Prox1 structure and inhibit IFN-γ 
expression [ 68 ]. The presence of Prox1 however is also notably downregulated as 
the cell differentiates into a CD4 + T cell, but the mechanism is unknown [ 68 ]. 
PPARγ and PPAR delta have also been reported to inhibit IFN-γ gene expression in 
part by antagonizing the activities of the transcription factors AP-1, STAT, and 
NF-kB [ 69 ,  70 ]. However, once IFN-γ has been expressed, it has been demonstrated 
to in turn suppress PPARγ expression via upregulation of activated STAT1 [ 71 ], 
thus forming a regulatory cycle to prevent under- or overexpression. 
 IFN-γ has been linked to many sex-biased autoimmune diseases and the sex bias 
in PPARγ coincides with these phenomena [ 72 ]. Males have a notably higher level 
of expression of PPARγ than females, thus contributing to the fi nding that female 
mice and women express more IFN-γ than their male counterparts [ 72 ]. 
1.5.2  TGF-B 
 Transforming growth factor beta (TGF-B) is a superfamily of cytokines that, when 
activated, downregulate the expression of T-bet mRNA via direct interaction of 
SMAD proteins with the T-bet promoter [ 73 ]. TGF-β utilizes SMAD2, SMAD3, 
and SMAD4 to suppress IFN-γ via inhibiting the activity of T-bet by binding to the 
proximal T-bet site in the IFN-γ locus [ 74 ]. 
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1.5.3  DREAM 
 Downstream regulatory element antagonist modulator (DREAM) can directly bind 
to the IFN-γ promoter and inhibit transcription. DREAM forms a complex with the 
related protein KChIP-2 around an area downstream of the TATA box in the IFN-γ 
promoter [ 75 ]. DREAM’s binding takes place as a doublet with one direct and one 
inverted downstream regulatory element located at position +20 downstream from 
the transcription initiation site if IFN-γ, thus blocking transcription [ 75 ]. DREAM 
is constitutively expressed in unstimulated T lymphocytes, and it has been reported 
that DREAM is rapidly downregulated after stimulation of T cells [ 75 ]. This sug-
gests DREAM may be important to prevent basal expression of IFN-γ when immune 
cells are not stimulated and are in a resting state. 
1.5.4  GATA3 
 Transacting T-cell-specifi c transcription factor GATA3 is a potent suppressor of 
IFN-γ and has effects on T-cell differentiation. Members of the CREB/ATF, AP-1, 
octamer 1, and GATA families of transcription factors bind to the proximal −70 bp 
to −47 bp and distal −98 bp to −72 bp regions upstream from the start site of IFN-γ 
transcription [ 76 ]. It has been reported that GATA3 restricts access to the promoter 
regions of IFN-γ and T-bet, thus preventing interactions of activating transcription 
factors with the IFN-γ promoter [ 76 ]. In addition, Gata3 and octamer 1 enhance the 
expression of IL-4-driving cell differentiation away from a state where IFN-γ is 
expressed [ 77 ]. 
 Published reports have promoted the idea that even though the binding of GATA3 
can be detected at two GATA motifs, in positions −108 bp to −91-bp, of the human 
IFN-γ gene, it may be that the lack of expression of IFN-γ in the presence of GATA3 
is more notably driven by the suppression of other transcription factors [ 76 ,  78 ]. Of 
note, there was a reduction in STAT4, involved in promoting IFN-γ transcription, in 
the presence of high levels of GATA3 [ 76 ]. Interestingly, these studies also showed 
a reduction of the amount of STAT1 in the cells expressing elevated levels of GATA3 
[ 78 ]. In addition, runt-related transcription factor 3 (Runx3) enhances the binding of 
T-bet to the IFN-γ locus by binding to specifi c regions in the IFN-γ promoter; this 
in turn decreases the binding frequency of GATA3 [ 79 ]. The binding of T-bet acts to 
competitively suppress GATA3 binding, thus enhancing IFN-γ transcription [ 79 , 
 80 ]. GATA3 has also been linked to changes in histone modulation, promoting 
access to some areas and restricting access to others in competition with T-bet [ 76 ]. 
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1.5.5  Yin Yang 1 
 Ying Yang 1, or YY1, is a zinc fi nger transcription factor that belongs to the human 
GLI-Kruppel family of nuclear proteins and is an inhibitor of the IFN-γ promoter in 
two notable models [ 81 ]. There are two constitutive YY1-binding sites in the IFN-γ 
promoter at positions Y1 −199 bp to −203 bp and Y2 −217 bp to −221 bp upstream 
from the transcriptional initiation site [ 81 ]. These sites are both hypothesized to 
play a role in inhibiting the expression of IFN-γ by competition for DNA binding 
with AP-1 at the Y1 position [ 64 ] and by activation of an AP-2-like protein by YY1 
binding at the Y2 position which then acts as a repressor of IFN-γ transcription [ 81 ]. 
1.6  Posttranscriptional Regulation 
 Posttranscriptional downregulation of IFN-γ is mostly characterized as being from 
processes degrading the IFN-γ mRNA. Removing the region in the 3′ UTR that 
contains the AUUA repeat elements (ARE) results in signifi cantly higher levels of 
expression of IFN-γ due to stabilization of the mRNA [ 82 ]. A second method of 
control involves the 5′ UTR region of the mRNA. As the structure of the 5′UTR has 
revealed the presence of a semi-knot, this structure triggers a natural anti-dsRNA 
reaction by RNA-activated protein kinase (PKR) which helps downregulate the con-
tinued expression of IFN-γ via binding to the mRNA and facilitating degradation of 
the dsRNA present in the semi-knot [ 83 ,  84 ]. 
 There are other forms of posttranscriptional controls for IFN-γ. A mechanism by 
which IFN-γ is posttranslationally modifi ed, i.e., glycosylation at positions 25 and 
97, stabilizes the protein and protects it from degradation [ 85 ]. In response to stress, 
the host cell can also change the protein’s fi nal structure, by downregulating the 
expression of the enzyme, Furin, which is needed to generate the IFN-γ protein into 
a functional state by cleaving the leader peptide [ 86 ]. This demonstrates that con-
trolling functional expression of this cytokine is a continuum of mechanisms that 
extend beyond the domain of transcription alone. 
1.7  Conclusions 
 Negative and positive controls of IFN-γ expression must remain in balance to pre-
vent the promotion of autoimmune diseases or host defi ciencies in fi ghting disease. 
The conserved nature and the wide-ranging effects of IFN-γ on the adaptive and 
innate immune systems ensure that the expression of IFN-γ is a potent response 
required to fi ght disease, but one that must be controlled in healthy hosts. This con-
trol is transcriptionally regulated at the level of chromatin access involving chroma-
tin secondary and tertiary structure, DNA methylation, and histone acetylation. This 
process is in turn effecting and affected by transcription factors, which are both 
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activators and inhibitors of gene expression. The specifi c host factors can be shaped 
by the process of transcription itself, as impacted by extracellular signals received 
by the target cells and RNA stability following gene induction. Understanding the 
labyrinthine system of controls may seem daunting, and the complete picture of 
IFN-γ control is still a point of active investigation. However, the more we learn 
about the control of this regulatory protein will allow us to apply this knowledge in 
the future to effectively manipulate IFN-γ expression for the treatment of infections, 
cancer, infl ammation, and autoimmune diseases. 
 (The author would like to apologize for any articles or work that was missed in 
the collection of this work. The volume of data, space, and time constraints made it 
impossible for the author to create a complete list of the valuable research that has 
been done on this integral part of immunological research.) 
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